Rubedo Life Sciences Initiates First-Ever GPX4 Modulator Clinical Trial for Psoriasis and Skin Aging
核心洞察
Rubedo Life Sciences (搜索) has dosed the first patient with RLS-1496, a novel GPX4 (搜索) modulator targeting pathological senescent cells (搜索), marking the first time this class of compounds has entered human clinical trials.
The Phase 1 trial will evaluate topical RLS-1496 in patients with plaque psoriasis (搜索) and skin aging, with potential expansion to other inflammatory skin conditions including atopic dermatitis (搜索), vitiligo (搜索), and alopecia areata (搜索).
Developed using Rubedo's AI-driven ALEMBIC™ platform, RLS-1496 represents a significant advancement in longevity science by selectively targeting "zombie cells" that drive chronic degenerative diseases associated with aging.
Rubedo Life Sciences (搜索) has announced the dosing of the first patient with its lead drug candidate RLS-1496 in a Phase 1 clinical trial, marking a significant milestone in longevity science. The trial represents the first time a GPX4 (搜索) (glutathione peroxidase) modulator targeting pathological senescent cells (搜索) has entered human clinical testing.
The single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial will assess the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496. The study is enrolling male and female patients 18 years or older with mild to moderate stable plaque psoriasis (搜索), whose aging skin will also be evaluated to determine if the treatment can improve biomarkers of aging and reverse the biological clock.
"We are excited to reach this important milestone not only for our lead candidate RLS-1496 but also for the advancement of longevity science," said Frederick Beddingfield, III, MD, PhD, FAAD, FACMS, CEO of Rubedo. "As the first company to treat patients with a GPX4 (搜索) modulator targeting senescent cells (搜索) in a data-rich Phase 1 clinical trial, we look forward to assessing its potential disease-altering effects on inflammatory skin conditions and skin aging."
Novel Mechanism Targeting "Zombie Cells"
RLS-1496 is a first-in-class disease-altering GPX4 (搜索) modulator that selectively targets pathological senescent cells (搜索), often referred to as "zombie cells," which drive inflammaging and chronic degenerative diseases associated with biological aging. These dysfunctional cells accumulate with age and contribute to various inflammatory conditions.
GPX4 (搜索) is a major antioxidant-regulating enzyme that protects cells and tissues from free radical damage and is essential for cell survival. In contrast, GPX4 deficiency is associated with regulated cell death (RCD), especially ferroptosis. By modulating GPX4 to selectively encourage cell death in ferroptosis-sensitive senescent cells (搜索), RLS-1496 may clear these harmful cells while supporting healthy cell function.
Marco Quarta, PhD, Rubedo's Chief Scientific Officer, highlighted the accelerated development timeline: "For the last decade, longevity scientists have been working to develop a compound ready for human trials that safely and effectively targets pathologic senescent cells (搜索). We are proud that our team developed RLS-1496 into a topical drug candidate in less than three years from initiation – two times faster than the industry average via ALEMBIC™, our proprietary AI-driven drug discovery platform with SenTeCh™ chemistry technology."
Trial Design and Future Applications
The Phase 1 trial will be conducted at a single center in The Netherlands with approximately 24 enrolled patients. The study will begin with single-dose applications followed by a multidose protocol. A key secondary objective is to evaluate the effects of RLS-1496 on target psoriasis lesions using the modified Investigator's Global Assessment (mIGA) to measure improvement.
Based on the results of this initial study, Rubedo plans to potentially expand the trial to additional inflammatory skin conditions and autoimmune disorders, including atopic dermatitis (搜索), vitiligo (搜索), rosacea (搜索), alopecia areata (搜索), and scleroderma (搜索). The company also has plans to advance a systemic formulation of RLS-1496 into Phase 1 clinical trials by 2026.
The trial design was developed with insights from Rubedo's Clinical Advisory Board, led by Chief Medical Officer and dermatologist Mary Spellman, MD. The advisory board includes prominent dermatologists Mark Lebwohl, MD, Ted Lain, MD, MBA, Zoe Draelos, MD, and Chris Griffiths, OBE MD FRCP.
Dr. Lebwohl, Professor & Chairman Emeritus of the Department of Dermatology at Icahn School of Medicine at Mount Sinai, expressed enthusiasm about the potential applications: "As clinicians, we are excited about the potential use of RLS-1496 as a topical treatment for psoriasis, other chronic inflammatory skin conditions, and skin aging itself. As researchers, we are intrigued by RLS-1496 as a potential first-in-class GPX4 (搜索) modulator that was designed to selectively target inflammaging pathologic senescent cells (搜索) and surrounding tissues."
Broader Implications for Age-Related Diseases
Beyond dermatological applications, Rubedo is developing RLS-1496 and other selective cellular rejuvenation medicines for a range of age-related conditions. The company's pipeline targets pathologic senescent cells (搜索) implicated in immunology and inflammation, metabolic syndrome (obesity, diabetes, liver fibrosis), sarcopenia, and neurodegenerative diseases.
Rubedo's approach represents a new frontier in treating chronic diseases by addressing their underlying biological aging mechanisms rather than merely managing symptoms. The company's ALEMBIC™ drug discovery platform combines artificial intelligence with novel chemistry to identify targets within pathologic senescent cells (搜索) and develop selective medicines.
As the first GPX4 (搜索) modulator to enter clinical trials, RLS-1496 positions Rubedo ahead of many leading biopharmaceutical companies evaluating the same target. This achievement underscores the potential of AI-driven drug discovery to accelerate the development of innovative therapies for age-related diseases.
The advancement of RLS-1496 into clinical trials marks a significant step forward in translating longevity science into potential therapeutic interventions that could fundamentally alter the course of chronic diseases associated with aging.